ArticleFrontiers in physiology2017
Interference with Ca
Article in Frontiers in physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- IGF-1 axis: The signalling bond in cancer-associated thrombosis and cachexia?Journal of thrombosis and thrombolysis · 2026Review
- Systematic Exploration of Molecular Mechanisms and Natural Herbal Therapeutic Strategies for Cancer Cachexia.Cancers · 2025Review
- Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways.International journal of molecular sciences · 2025Review
- Advancing cancer cachexia diagnosis with -omics technology and exercise as molecular medicine.Sports medicine and health science · 2024Review
- Calpain/calpstatin pathway in COVID-19: Role of dantrolene.Journal of cellular and molecular medicine · 2024Article
- Cancer cachexia: molecular mechanisms and treatment strategies.Journal of hematology & oncology · 2023Review
- A triple-masked, two-center, randomized parallel clinical trial to assess the superiority of eight weeks of grape seed flour supplementation against placebo for weight loss attenuation during perioperative period in patients with cachexia associated with colorectal cancer: a study protocol.Frontiers in endocrinology · 2023Article
- Review
- Review
- Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.Journal of cachexia, sarcopenia and muscle · 2021Review
- Lack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model.OncoTargets and therapy · 2021Article
- Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review).Molecular medicine reports · 2020Review
- Interleukin-4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma-bearing mice.Journal of cachexia, sarcopenia and muscle · 2020Article
- The Skeletal Muscle as an Active Player Against Cancer Cachexia.Frontiers in physiology · 2019Review
- Molecular Insights into Muscle Homeostasis, Atrophy and Wasting.Current genomics · 2018Review
- Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.Oxidative medicine and cellular longevity · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein hypercatabolism significantly contributes to the onset and progression of muscle wasting in cancer cachexia. In this regard, a major role is played by the ATP-ubiquitin-proteasome-dependent pathway and by autophagy. However, little is known about the relevance of the Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.